Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Kodiak Sciences Inc (KOD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Kodiak Sciences's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.370 +0.090    +2.74%
29/04 - Closed. Currency in USD ( Disclaimer )
After Hours
3.470
+0.100
+2.967%
0:06:35 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 307,291
  • Bid/Ask: 3.300 / 3.480
  • Day's Range: 3.255 - 3.480
Kodiak Sciences 3.370 +0.090 +2.74%

Kodiak Sciences Inc Company Profile

 
Get an in-depth profile of Kodiak Sciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

116

Equity Type

ORD

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company’s preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Contact Information

Address 1200 Page Mill Road
Palo Alto, 94304
United States
Phone 650 281 0850
Fax -

Top Executives

Name Age Since Title
Charles Wykoff - - Scientific Advisor
Felix James Baker 54 2015 Independent Director
Taiyin Yang 69 2019 Independent Director
David Brown - - Scientific Advisor
Bassil I. Dahiyat 53 2018 Independent Director
Robert A. Profusek 73 2018 Lead Independent Director
Carl Regillo - - Scientific Advisor
Michael IP - - Scientific Advisor
David Boyer - - Scientific Advisor
Richard S. Levy 65 2018 Independent Director
Pravin Dugel - - Scientific Advisor
Charles A. Bancroft 63 2020 Independent Director
Sunil Patel - - Scientific Advisor
Victor Perlroth 50 2009 Co-Founder, Chairman, CEO & President
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

KOD Comments

Write your thoughts about Kodiak Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email